Amicus Therapeutics Stock Price History
FOLD Stock | USD 9.49 0.30 3.26% |
Below is the normalized historical share price chart for Amicus Therapeutics extending back to May 31, 2007. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Amicus Therapeutics stands at 9.49, as last reported on the 1st of March, with the highest price reaching 9.50 and the lowest price hitting 9.14 during the day.
If you're considering investing in Amicus Stock, it is important to understand the factors that can impact its price. Amicus Therapeutics secures Sharpe Ratio (or Efficiency) of -0.03, which signifies that the company had a -0.03 % return per unit of risk over the last 3 months. Amicus Therapeutics exposes twenty-eight different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Amicus Therapeutics' Risk Adjusted Performance of 0.0128, downside deviation of 2.39, and Mean Deviation of 1.3 to double-check the risk estimate we provide.
At present, Amicus Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Common Stock is expected to grow to about 3.1 M, whereas Liabilities And Stockholders Equity is forecasted to decline to about 491.9 M. . At present, Amicus Therapeutics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 15.52, whereas Price Earnings Ratio is projected to grow to (48.55). Amicus Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 31st of May 2007 | 200 Day MA 10.2881 | 50 Day MA 9.5216 | Beta 0.607 |
Amicus |
Sharpe Ratio = -0.03
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | FOLD |
Estimated Market Risk
2.01 actual daily | 17 83% of assets are more volatile |
Expected Return
-0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Amicus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amicus Therapeutics by adding Amicus Therapeutics to a well-diversified portfolio.
Price Book 14.5509 | Enterprise Value Ebitda 102.6654 | Price Sales 5.5191 | Shares Float 249.7 M | Wall Street Target Price 16.7273 |
Amicus Therapeutics Stock Price History Chart
There are several ways to analyze Amicus Stock price data. The simplest method is using a basic Amicus candlestick price chart, which shows Amicus Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
Highest Price | December 11, 2024 | 10.16 |
Lowest Price | January 10, 2025 | 9.02 |
Amicus Therapeutics March 1, 2025 Stock Price Synopsis
Various analyses of Amicus Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Amicus Stock. It can be used to describe the percentage change in the price of Amicus Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Amicus Stock.Amicus Therapeutics Price Action Indicator | 0.32 | |
Amicus Therapeutics Accumulation Distribution | 115,084 | |
Amicus Therapeutics Price Daily Balance Of Power | 0.83 | |
Amicus Therapeutics Price Rate Of Daily Change | 1.03 |
Amicus Therapeutics March 1, 2025 Stock Price Analysis
Amicus Stock Price History Data
The price series of Amicus Therapeutics for the period between Sun, Dec 1, 2024 and Sat, Mar 1, 2025 has a statistical range of 1.14 with a coefficient of variation of 2.8. Under current investment horizon, the daily prices are spread out with arithmetic mean of 9.6. The median price for the last 90 days is 9.64. The company completed dividends distribution on 2009-08-31.Open | High | Low | Close | Volume | ||
02/28/2025 | 9.22 | 9.50 | 9.14 | 9.49 | 3,036,949 | |
02/27/2025 | 9.00 | 9.42 | 8.92 | 9.19 | 2,374,716 | |
02/26/2025 | 9.07 | 9.18 | 9.00 | 9.03 | 1,567,224 | |
02/25/2025 | 9.42 | 9.55 | 9.09 | 9.11 | 2,307,272 | |
02/24/2025 | 9.16 | 9.56 | 9.00 | 9.34 | 3,730,640 | |
02/21/2025 | 9.15 | 9.26 | 9.02 | 9.19 | 2,603,411 | |
02/20/2025 | 9.42 | 9.64 | 9.06 | 9.07 | 3,321,922 | |
02/19/2025 | 9.11 | 10.00 | 9.07 | 9.56 | 4,437,979 | |
02/18/2025 | 9.73 | 9.94 | 9.68 | 9.85 | 2,490,153 | |
02/14/2025 | 9.68 | 9.82 | 9.65 | 9.77 | 1,944,625 | |
02/13/2025 | 9.63 | 9.72 | 9.49 | 9.64 | 1,782,509 | |
02/12/2025 | 9.38 | 9.59 | 9.35 | 9.55 | 2,927,962 | |
02/11/2025 | 9.54 | 9.65 | 9.32 | 9.57 | 2,918,602 | |
02/10/2025 | 9.69 | 9.73 | 9.47 | 9.64 | 2,110,970 | |
02/07/2025 | 9.84 | 9.84 | 9.50 | 9.65 | 2,826,031 | |
02/06/2025 | 9.78 | 9.91 | 9.68 | 9.83 | 2,385,274 | |
02/05/2025 | 9.80 | 9.95 | 9.66 | 9.78 | 1,843,664 | |
02/04/2025 | 9.62 | 9.85 | 9.61 | 9.76 | 1,311,567 | |
02/03/2025 | 9.44 | 9.68 | 9.39 | 9.64 | 1,503,915 | |
01/31/2025 | 9.62 | 9.73 | 9.56 | 9.58 | 1,743,009 | |
01/30/2025 | 9.63 | 9.80 | 9.53 | 9.64 | 1,627,045 | |
01/29/2025 | 9.60 | 9.72 | 9.47 | 9.59 | 1,683,979 | |
01/28/2025 | 9.66 | 9.81 | 9.60 | 9.66 | 1,964,198 | |
01/27/2025 | 9.61 | 9.83 | 9.57 | 9.68 | 1,831,330 | |
01/24/2025 | 9.60 | 9.74 | 9.43 | 9.61 | 1,887,373 | |
01/23/2025 | 9.45 | 9.73 | 9.41 | 9.65 | 1,864,692 | |
01/22/2025 | 9.50 | 9.61 | 9.47 | 9.54 | 1,635,456 | |
01/21/2025 | 9.50 | 9.63 | 9.40 | 9.51 | 1,774,523 | |
01/17/2025 | 9.46 | 9.46 | 9.21 | 9.41 | 1,610,164 | |
01/16/2025 | 9.26 | 9.47 | 9.19 | 9.36 | 2,265,083 | |
01/15/2025 | 9.35 | 9.41 | 9.12 | 9.27 | 2,504,613 | |
01/14/2025 | 9.20 | 9.39 | 9.10 | 9.21 | 4,134,129 | |
01/13/2025 | 9.44 | 9.44 | 8.79 | 9.23 | 3,587,088 | |
01/10/2025 | 9.34 | 9.34 | 8.85 | 9.02 | 3,244,248 | |
01/08/2025 | 9.37 | 9.54 | 9.15 | 9.46 | 2,820,828 | |
01/07/2025 | 9.33 | 9.54 | 9.29 | 9.36 | 1,600,118 | |
01/06/2025 | 9.41 | 9.49 | 9.28 | 9.30 | 1,636,312 | |
01/03/2025 | 9.32 | 9.52 | 9.27 | 9.41 | 1,692,753 | |
01/02/2025 | 9.48 | 9.57 | 9.29 | 9.31 | 2,349,968 | |
12/31/2024 | 9.45 | 9.49 | 9.35 | 9.42 | 1,363,978 | |
12/30/2024 | 9.57 | 9.57 | 9.32 | 9.41 | 1,224,902 | |
12/27/2024 | 9.69 | 9.79 | 9.55 | 9.63 | 1,651,179 | |
12/26/2024 | 9.73 | 9.84 | 9.65 | 9.77 | 1,130,720 | |
12/24/2024 | 9.81 | 9.86 | 9.62 | 9.79 | 921,056 | |
12/23/2024 | 9.73 | 9.84 | 9.66 | 9.84 | 1,464,014 | |
12/20/2024 | 9.68 | 9.88 | 9.60 | 9.80 | 4,077,528 | |
12/19/2024 | 9.58 | 9.87 | 9.44 | 9.73 | 2,616,135 | |
12/18/2024 | 9.87 | 9.93 | 9.41 | 9.57 | 2,616,218 | |
12/17/2024 | 9.86 | 9.97 | 9.72 | 9.89 | 1,946,241 | |
12/16/2024 | 9.37 | 9.99 | 9.28 | 9.90 | 3,495,587 | |
12/13/2024 | 9.85 | 9.91 | 9.30 | 9.36 | 4,100,547 | |
12/12/2024 | 10.06 | 10.20 | 10.02 | 10.15 | 2,156,761 | |
12/11/2024 | 10.14 | 10.36 | 10.09 | 10.16 | 1,937,488 | |
12/10/2024 | 9.87 | 10.20 | 9.82 | 10.13 | 3,000,240 | |
12/09/2024 | 9.76 | 10.00 | 9.74 | 9.83 | 7,813,576 | |
12/06/2024 | 9.82 | 9.97 | 9.57 | 9.73 | 6,562,299 | |
12/05/2024 | 9.80 | 9.89 | 9.72 | 9.76 | 1,730,897 | |
12/04/2024 | 9.80 | 9.99 | 9.75 | 9.86 | 1,685,215 | |
12/03/2024 | 9.90 | 9.99 | 9.72 | 9.79 | 2,068,442 | |
12/02/2024 | 9.96 | 10.15 | 9.92 | 9.96 | 1,997,520 | |
11/29/2024 | 9.96 | 10.03 | 9.93 | 9.98 | 818,677 |
About Amicus Therapeutics Stock history
Amicus Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Amicus is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Amicus Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Amicus Therapeutics stock prices may prove useful in developing a viable investing in Amicus Therapeutics
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 304.4 M | 319.6 M | |
Net Loss | -212.9 M | -223.6 M |
Amicus Therapeutics Quarterly Net Working Capital |
|
Amicus Therapeutics Stock Technical Analysis
Amicus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
All Next | Launch Module |
Amicus Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Amicus Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Amicus Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Amicus to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | 0.0128 | |||
Jensen Alpha | 0.0254 | |||
Total Risk Alpha | 0.0679 | |||
Sortino Ratio | 0.0127 | |||
Treynor Ratio | 0.0092 |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
CEOs Directory Screen CEOs from public companies around the world | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |